During the past decade, San Diego Cardiovascular Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "San Diego Cardiovascular Associates" are "Atrial Fibrillation" (1 trials) and "Coronary Artery Disease" (1 trials). Many other conditions were trialed in "San Diego Cardiovascular Associates" in a lesser frequency.

Most popular intervention types in "San Diego Cardiovascular Associates" are "Device" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Azimilide Dihydrochloride" (1 trials), "Placebo" (1 trials), "TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent" (1 trials) and "XIENCE V® Everolimus Eluting Coronary Stent" (1 trials). Other intervention names were less common.

The vast majority of trials in "San Diego Cardiovascular Associates" are 2 trials for "All" genders.

Currently, there are NaN active trials in "San Diego Cardiovascular Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in San Diego Cardiovascular Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in San Diego Cardiovascular Associates, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".